Published 12 hours ago • loading... • Updated 12 hours ago

GLP-1 Medications for Weight Loss: What the Trials Show and What Patients Should Ask Firs

What the STEP 1, SURMOUNT-1 and SELECT trials show about semaglutide and tirzepatide, the side effects to expect, and what to ask before starting.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

medicalresearch.com

GLP-1 Medications for Weight Loss: What the Trials Show and What Patients Should Ask Firs

What the STEP 1, SURMOUNT-1 and SELECT trials show about semaglutide and tirzepatide, the side effects to expect, and what to ask before starting.

12 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated11 hours agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

medicalresearch.com broke the news 12 hours ago on Sunday, November 8, 2026.

Sources are mostly out of (0)

GLP-1 Medications for Weight Loss: What the Trials Show and What Patients Should Ask Firs

1 Articles

1 Articles

GLP-1 Medications for Weight Loss: What the Trials Show and What Patients Should Ask Firs

Coverage Details

Bias Distribution

Factuality

Ownership

More stories like this

Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity

‘Feeling really weak and shaky’: Experts warn of malnutrition risks on GLP-1s

New Slimming Pen Arrives at Pharmacies for R$ 333; Learn More

Peptide Nerds Went Looking for the Best GLP-1 Providers. Then They Found the Fine Print.

Nvidia opens probe of CEO Huang being targeted by possible Chinese spy

Nandy acknowledges ‘trade-offs’ for Britain if it gets closer to EU

Similar News Topics

Similar News Topics

More stories like this

Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity

‘Feeling really weak and shaky’: Experts warn of malnutrition risks on GLP-1s

New Slimming Pen Arrives at Pharmacies for R$ 333; Learn More

Peptide Nerds Went Looking for the Best GLP-1 Providers. Then They Found the Fine Print.

Nvidia opens probe of CEO Huang being targeted by possible Chinese spy

Nandy acknowledges ‘trade-offs’ for Britain if it gets closer to EU

GLP-1 Medications for Weight Loss: What the Trials Show and What Patients Should Ask Firs

1 Articles

1 Articles

GLP-1 Medications for Weight Loss: What the Trials Show and What Patients Should Ask Firs

Coverage Details

Bias Distribution Too Big Arrow Icon

Factuality Info Icon

Ownership

More stories like this

Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity

‘Feeling really weak and shaky’: Experts warn of malnutrition risks on GLP-1s

New Slimming Pen Arrives at Pharmacies for R$ 333; Learn More

Peptide Nerds Went Looking for the Best GLP-1 Providers. Then They Found the Fine Print.

Nvidia opens probe of CEO Huang being targeted by possible Chinese spy

Nandy acknowledges ‘trade-offs’ for Britain if it gets closer to EU

Similar News Topics

Similar News Topics

More stories like this

Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity

‘Feeling really weak and shaky’: Experts warn of malnutrition risks on GLP-1s

New Slimming Pen Arrives at Pharmacies for R$ 333; Learn More

Peptide Nerds Went Looking for the Best GLP-1 Providers. Then They Found the Fine Print.

Nvidia opens probe of CEO Huang being targeted by possible Chinese spy

Nandy acknowledges ‘trade-offs’ for Britain if it gets closer to EU

Bias Distribution

Factuality